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Staphylococcal nuclease domain containing-1 (SND1) is overexpressed in human hepatocellular car-
cinoma (HCC) patients and promotes tumorigenesis by human HCC cells. We now document that
SND1 increases angiotensin II type 1 receptor (AT1R) levels by increasing AT1R mRNA stability. This
results in activation of ERK, Smad2 and subsequently the TGFb signaling pathway, promoting epithe-
lial–mesenchymal transition (EMT) and migration and invasion by human HCC cells. A positive cor-
relation was observed between SND1 and AT1R expression levels in human HCC patients. Small
molecule inhibitors of SND1, alone or in combination with AT1R blockers, might be an effective
therapeutic strategy for late-stage aggressive HCC.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Hepatocellular carcinoma is the ﬁfth most common cancer and
the third most leading cause of cancer associated mortality in the
world [1,2]. It is a highly aggressive disease and poses a major
health problem because of its constantly increasing incidence
and its poor prognosis owing to the lack of any effective treatment
for the invasive and metastatic disease [2–4]. Its association with
metabolic syndromes, such as diabetes, obesity, and non-alcoholic
steatohepatitis (NASH), has made HCC an even major risk for life[5]. Elucidation of the molecular mechanism of aggressive HCC is
the need of the time for developing molecular targeted therapies
exerting lasting beneﬁcial effect to the patients.
Staphylococcal nuclease domain containing-1 (SND1) is a mul-
tifaceted protein that regulates various intracellular processes,
such as RNA interference as a nuclease in the RNA-induced silenc-
ing complex (RISC), mRNA splicing and stability, and transcription
as a co-activator [6]. Recent studies have started to unravel the role
of SND1 in carcinogenesis of diverse organs [7–11]. SND1 expres-
sion gradually increases with the stages and grades of cancer and
its overexpression is associated with highly aggressive metastatic
disease [9–11]. In our previous studies we documented that in
109 human HCC samples SND1 was overexpressed in 74% cases
compared to normal liver [11]. Correspondingly, in human HCC
cells a signiﬁcantly higher RISC activity was observed which was
associated with increased degradation of tumor suppressor mRNAs
that are target of oncomiRs thereby contributing to hepatocarcino-
genesis [11]. Stable overexpression of SND1 augmented and siRNA-
mediated inhibition of SND1 abrogated growth of human HCC cells
in vitro and in vivo in nude mice xenograft studies [11]. SND1
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induction of miR-221 and angiogenic factors Angiogenin and
CXCL16 [12]. These studies indicate that SND1 promotes aggres-
sive HCC by multiple ways.
Angiotensin II (AngII), generated from angiotensin I (AngI) by
angiotensin-I converting enzyme (ACE), and angiotensin II type 1
receptor (AT1R) play an important role in regulating hepatic ﬁbro-
sis and eventual hepatocarcinogenesis by modulating functions of
hepatic stellate cells [13–15]. AngII/AT1R has been shown to
induce proliferation of human HCC cells via a cross-talk with epi-
dermal growth factor receptor (EGFR) [16]. AngII also induces
transforming growth factor-b (TGFb) [17], a potent driver of cancer
progression through the induction of epithelial–mesenchymal
transition (EMT), in which epithelial cells acquire mesenchymal
phenotype, leading to enhanced motility and invasion [18]. ACE
inhibitors (ACE-I) and AT1R blockers demonstrated signiﬁcant
inhibitory effects on experimental murine liver ﬁbrosis and HCC
development [19,20]. A combination of ACE-I and vitamin K2 has
been shown to signiﬁcantly ameliorate cumulative recurrence of
HCC [21].
In the present studies we document that SND1 increases AT1R
level by augmenting AT1R mRNA stability leading to activation of
TGFb downstream signaling. The net effect of this pathway is induc-
tion of EMT contributing to increased migration and invasion by
human HCC cells. We also document a positive correlation between
SND1 and AT1R expression in human HCC patients. Inhibition of
enzymatic activity of SND1 along with ACE-I and AT1R blockers
might be an effective way to counteract a fatal malady like HCC.2. Materials and methods
2.1. Cell lines and culture condition
Hep3B cells were obtained from ATCC and were cultured as rec-
ommended. The human HCC cell line QGY-7703, developed at
Fudan University, Shanghai, was obtained from Dr. Zhao-zhong
Su, and Huh7 cells were kindly provided by Dr. Paul Dent and were
cultured as described [22]. The generation of the Hep3B-Con,
Hep3B-SND1-17, Hep3B-SND1-9, QGY-Consi, QGY-SND1si-12 and
QGY-SND1si-15 was described before [11,12]. Huh7 cells were
transduced with a pool of three to ﬁve lentiviral vector plasmids,
each encoding target-speciﬁc 19–25 nt (plus hairpin) shRNAs
designed to knockdown SND1 gene expression (Santa Cruz Bio-
technology). The cells were then selected for 2 weeks in 1 lg/ml
puromycin and individual colonies (Huh7-SND1si) were isolated,
expanded and maintained in 0.25 lg/ml puromycin. Similar strat-
egy was used to generate Huh7-Consi clones. Hep3B-SND1-17 cells
were transfected with plasmids expressing AT1R shRNA and stable
clones (SND1-17-AT1Rsi) were generated by selection with 1 lg/
ml puromycin. Similar strategy using control shRNA expressing
plasmid was employed to generate SND1-17-Consi clones.
2.2. Chemicals and plasmids
Losartan potassium was obtained from Tocris Biosciences
(Ellisville, MO, Catalogue# 3798) and used at a concentration of
10 lM. PD183452 was obtained from Sellecchem.com (Houston,
TX, Catalogue# CI-1040) and used at a concentration of 20 lM.
Recombinant human PAI-1 (Catalogue# 1786-PI-010) and TGFb
(Catalogue# 240-B-010) were obtained from R&D Systems (Min-
neapolis, MN) were used at concentrations of 20 and 1 nmol/ml,
respectively. Actinomycin D was obtained from Sigma–Aldrich
(St. Louis, MO, Catalogue# A1420) and used at a concentration
of 5 lg/ml. Human PAI-1 promoter-luciferase reporter constructs,
p800-luc and p549-luc, were kind gifts from Dr. Fahumiya Samad(Torrey Pines Institute for Molecular Studies, San Diego, CA).
p800-luc contains 800 to +71 region of the promoter and
p549-luc contains 549 to +71 region of the promoter lacking 2
SMAD, 1 AP-1 and 1 NF-jB binding sites compared to p800-luc
[23]. Human AT1R (Catalogue# sc-29750) and PAI-1 (Catalogue#
sc-36179) siRNAs and plasmids expressing scrambled shRNA
(Catalogue# sc-108060) and AT1R shRNA plasmid (Catalogue#
sc-29750-SH) were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA).
2.3. Migration assays
A wound healing/scratch assay was used to evaluate cell migra-
tion [24]. Conﬂuent cells were scratched with a 200 ll micropi-
pette tip to create a cell-free area. The scratched monolayers
images were captured at 0 and 24 h after wounding using an
Olympus IX-50 microscope equipped with a Variocam camera. Cell
migration distance was determined by measuring the wound
width and subtracting this from the initial value using ImageJ
software. A total of six areas were randomly selected in each well,
and the cells in three wells of either group were quantiﬁed in each
experiment. Cells were treated with rPAI-1, TGFb, LP or PD183452
for 24 h before scratch was made. Cells were transfected with
PAI-1 siRNA, plated on 6-well plates after 24 h and scratch was
made after another 24 h.
2.4. Invasion assays
Invasion was measured by using 24-well BioCoat cell culture
inserts with an 8-l-porosity polyethyleneterepthalate membrane
coated with Matrigel basement membrane matrix (100 lg/cm2)
(BD Biosciences, Franklin Lakes, NJ) [22]. Brieﬂy, the Matrigel was
allowed to rehydrate for 2 h at room temperature by adding warm,
serum-free DMEM. The wells of the lower chamber were ﬁlled
with medium containing 5% FBS. Cells (5  104) were seeded in
the upper compartment (6.25-mm membrane size) in serum-free
medium. The invasion assay was performed at 37 C in a 5% CO2
humidiﬁed incubator for 22 h. At the end of the invasion assay,
the ﬁlters were removed, ﬁxed, and stained with the Diff-Quick
staining kit. Cells on the upper surface of the ﬁlters were removed
by wiping with a cotton swab, and invasion was determined by
counting the number of cells that migrate to the lower side of
the ﬁlter with a microscope at 100magniﬁcation. Cells were trea-
ted with rPAI-1 (20 nmol/ml), TGFb (1 nmol/ml), losartan potas-
sium (LP, 10 lM) or PD183452 (20 lM) for 24 h before plating on
the invasion chamber. Cells were transfected with PAI-1 siRNA
and 48 h later plated on the invasion chamber.
2.5. Tissue microarray and immunohistochemistry
Human HCC tissue microarray, containing 40 primary HCC, 10
metastatic HCC and 9 normal adjacent liver samples was obtained
from Imgenex Corp (San Diego, CA, Catalogue# IMH-360) [22]. Out
of the 50 HCC samples, 14 belongs to Stage I, 9 belongs to Stage II,
14 belongs to Stage III and 13 belongs to Stage IV. Following depar-
afﬁnization, the sections were permeabilized with a 0.1% TritonX-
100 solution in PBS for 30 min. Sections were then blocked for 1 h
at room temperature with 2% goat serum and 1% BSA in PBS and
incubated with anti-SND1 antibody (rabbit polyclonal; 1:100;
Prestige Antibodies Powered by Atlas Antibodies from Sigma) or
anti-AT1R antibody (1:200; rabbit polyclonal; Abnova) overnight
at 4 C. Sections were then rinsed in PBS, and incubated with
anti-rabbit secondary antibody for 1 h at room temperature. The
signals were developed by avidin–biotin–peroxidase complexes
with a DAB substrate solution (Vector laboratories). The images
were taken by an Olympus microscope.
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Preparation of whole cell lysates and Western blot analyses
were performed as described [22]. The following rabbit primary
antibodies were obtained from Cell signaling Technology (Danver,
MA) and used at a dilution of 1:1000: E-cadherin (#4065), N-cad-
herin (#4061), Slug (C19G7 monoclonal, #9585), Snail (C15D3
monoclonal, #3879), Vimentin (R28, #3932), phospho-p44/42
MAPK (Erk1/2, #4370), p44/42 MAPK (Erk1/2, #4695), phospho-
SMAD2 (#3104) and SMAD2/3 (D7G7 monoclonal, #8685). The
other primary antibodies used were SND1 (rabbit polyclonal,
1:1000, Sigma), AT1R (rabbit polyclonal, 1:1000, Abnova), GAPDH
(rabbit polyclonal, 1:1000, Santa Cruz), b-actin (mouse monoclo-
nal, 1:2000, Sigma) and EF1-a (mouse monoclonal, 1:1000, Milli-
pore). Densitometric analysis was performed by ImageJ software.
2.7. Cell viability and clonogenic assays
Cell viability was determined by standard 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays as
described [22]. For colony formation assay, cells (1  103) were
plated in 6-cm dishes and colonies >50 cells were counted after
2 weeks [22].
2.8. Total RNA extraction, real time PCR and Affymetrix microarray
Total RNA was extracted using Qiagen miRNAeasy mini kit (Qia-
gen, Valencia, CA). Real time PCR was performed using an ABI 7900
fast real time PCR system and Taqman gene expression assays for
AT1R and GAPDH according to the manufacturer’s protocol (Life
Technologies). Total RNA was used to perform Affymetrix Oligonu-
cleotide Microarray (Human U133 plus 2.0) between QGY-Consi
versus QGY-SND1si-12 and QGY-SND1si-15 clones according to
the manufacturer’s instructions. The standard Affymetrix protocol
was used for generation of fragmented labeled cRNA for hybridiza-
tion. The HG-U133A 2.0 array provides comprehensive coverage of
the transcribed human genome by including 22,277 probe sets that
analyze the expression level of over 18,400 human transcripts.
Data analysis was performed as described [25]. The data have been
submitted to GEO with accession number GSE44601. The expres-
sion of genes that showed a false discovery rate (FDR; q-value) 0
and p-value <0.001 was presented in Table S1.
2.9. Human angiogenesis array
The expression levels of 55 angiogenesis associated proteins
were analyzed using conditioned media from cells cultured in
serum-free condition with the Human Angiogenesis Antibody
Array kit (R&D Systems, Proteome Proﬁler TM) as recommended
by the manufacturer [12]. The cells were pretreated with
PD183452 for 2 h.
2.10. Enzyme-linked immunosorbent assay (ELISA)
The expression of TGFb and PAI-1 were analyzed in conditioned
media using ELISA kits (R&D Systems, Quantakine R) as recom-
mended by the manufacturer. Cells were transfected with AT1R
siRNA, 48 h later medium was replaced by serum-free media to
which LP was added and PAI-1 level was measured after 24 h.
2.11. Transient transfection and luciferase assays
Cells (1  105) were plated in each well of a 24-well tissue cul-
ture plate. Next day transfection was performed using Lipofect-
amine 2000 Reagent (Life Technologies, Grand Island, NY)
with 950 ng of luciferase reporter plasmid and 50 ng of Renillaluciferase plasmid as internal control for each well. The cells were
treated or not with TGFb (1 nmol/ml) for 48 h. Luciferase activity
was measured using a Dual Luciferase Reporter Assay kit (Promega,
Madison, WI) according to the manufacturer’s protocol and ﬁreﬂy
luciferase activity was normalized by Renilla luciferase activity.
2.12. Statistical analysis
Data were represented as the mean ± Standard Error of Mean
(S.E.M) and analyzed for statistical signiﬁcance using one-way
analysis of variance (ANOVA) followed by Newman–Keuls test as
a post hoc test. To assess the strength of association between
SND1 and AT1R an ordinal logistic regression was conducted with
SND1 expression Pearson’s v2 goodness of ﬁt test with 6 degrees of
freedom was performed.
3. Results
3.1. SND1 promotes migration and invasion of human HCC cells
We previously documented that Hep3B and QGY-7703 cells
express low and high levels of SND1, respectively [11]. Stable over-
expression of SND1 in Hep3B cells signiﬁcantly augments while
stable knockdown of SND1 in QGY-7703 cells signiﬁcantly inhibits
in vitro proliferation, angiogenesis and formation of subcutaneous
xenografts in athymic nude mice [11,12]. These ﬁndings were
observed in multiple clones of SND1-overexpressing Hep3B cells
as well as SND1-knockdown QGY-7703 cells and these clones have
been characterized in detail [11,12]. In the present study we
employed these clones as well as clones of Huh7 cells, which
express high level of SND1, with stable knockdown of SND1. Stable
overexpression of SND1 in Hep3B cells induced a morphological
change with elongated, spindle-shaped, ﬁbroblast-like cells while
stable knockdown of SND1 in QGY-7703 and Huh7 cells induced
a blunted morphology (Fig. 1A) suggesting that SND1 might affect
cell motility and thereby migration and invasion, two major deter-
minants of an aggressive cancer. To analyze migration and inva-
sion, we performed wound healing assay and Matrigel invasion
assay, respectively, using the established clones. A signiﬁcant
increase in migration and invasion was observed in SND1 over-
expressing Hep3B-SND1-17 clone compared to the control Hep3B
clone (Hep3B-Con) (Fig. 1B and C). As a corollary a signiﬁcant
decrease in migration and invasion was observed in SND1 knock-
down clones QGY-SND1si-12 and Huh7-SND1si-7 when compared
to the control clones QGY-Consi and Huh7-Consi, expressing con-
trol siRNA, respectively (Fig. 1B and C). Similar ﬁnding was
observed in additional SND1-overexpressing and SND1 knockdown
clones (Fig. S1).
3.2. SND1 modulates TGFb signaling pathway
To get an insight into the molecular mechanism by which SND1
modulates migration and invasion gene expression proﬁles were
compared between QGY-Consi versus QGY-SND1si-12 and QGY-
SND1si-15 clones by Affymetrix oligonucleotide microarray
(Human U133 plus 2.0). We focused on those genes that were
downregulated in SND1 knockdown clones compared to the con-
trol clone. Using a q-value of 0, we observed signiﬁcant downreg-
ulation of 123 genes upon SND1 knockdown (Table S1).
Interestingly we observed signiﬁcant downregulation of several
Transforming Growth Factor b (TGFb) downstream genes, such as
TAGLN, NUPR1, IGFBP3 and KLF6 [26], in SND1 knockdown clones
compared to the control clones. Since TGFb is a known regulator of
cell motility, migration and epithelial–mesenchymal transition
(EMT) [18] we focused our work on unraveling the role of TGFb
in SND1-mediated augmentation of migration and invasion as well
Fig. 1. SND1 promotes migration and invasion of human HCC cells. (A) Photomicrograph of the indicated cells, magniﬁcation 200. (B) Graphical representation of the
migration ability of the indicated cells when the migration ability of QGY-Consi clone was considered as 100%. (C) Graphical representation of the Matrigel invasion assay
performed in the indicated cells. (D and E) TGFb (D) and PAI-1 (E) levels in the conditioned media of the indicated cells determined by ELISA. For B–E, data represent
mean ± SEM of 3 independent experiments. ⁄ p < 0.01.
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bolstered by our previous observations using an angiogenesis array
that SND1 signiﬁcantly induces Plasminogen Activator Inhibitor-1
(PAI-1) [12], a known TGFb-downstream gene promoting migra-
tion and invasion of tumor cells [27].
We ﬁrst conﬁrmed regulation of TGFb and PAI-1 by SND1 by
determining TGFb and PAI-1 levels in conditioned media of SND1
overexpressing and SND1 knockdown clones using ELISA.
Indeed, TGFb and PAI-1 levels were signiﬁcantly increased in
Hep3B-SND1-17 clone compared to Hep3B-Con clone while those
levels were signiﬁcantly decreased in QGY-SND1si-12 and
Huh7-SND1si-7 clones compared to QGY-Consi and Huh7-Consi
clones, respectively (Fig. 1D and E). Knocking down PAI-1 by siRNA
in Hep3B-SND1-17 clone and QGY-7703 cells signiﬁcantly
decreased migration and invasion while treatment of Hep3B and
QGY-SND1si-12 cells with recombinant PAI-1 signiﬁcantly
increased migration and invasion (Fig. 2A–F). As a corollary treat-
ment with TGFb signiﬁcantly increased migration and invasion of
Hep3B cells and QGY-SND1si-12 clone (Fig. 2C–F). Since TGFb is
a known regulator of epithelial-mesenchymal transition (EMT)
we checked the expression of EMT markers in these clones. The
level of E-cadherin did not change signiﬁcantly upon SND1 overex-
pression in Hep3B cells while it was not detected in QGY-7703 cells
(Fig. 2G). However, E-cadherin level increased signiﬁcantly in
Huh7-SND1si-7 clone when compared to parental Huh7 cells or
Huh7-Consi clone (Fig. 2G). The levels of N-cadherin, Slug, Snail
and Vimentin increased signiﬁcantly in Hep3B-SND1-17 clone
when compared to Hep3B-Con clone while those levels decreased
signiﬁcantly in QGY-SND1si-12 and Huh7-SND1si-7 clones when
compared to QGY-Consi and Huh7-Consi clones, respectively, indi-
cating that SND1 plays an important role in regulating EMT
(Fig. 2G).To check transcriptional regulation of PAI-1 by SND1 and TGFb
we analyzed PAI-1 promoter-luciferase activity using two reporter
constructs, p800-luc containing 800 to +71 region of the pro-
moter and p549-luc containing549 to +71 region of the promoter
[23]. p549-luc construct lacks 2 SMAD, 1 AP-1 and 1 NF-jB binding
sites compared to p800-luc [23]. Under basal condition the activity
of p800-luc showed 2-fold induction in Hep3B-SND1-17 clone
when compared to Hep3B-Con clone (Fig. 2H). Upon TGFb treat-
ment p800-luc activity increased by 85-fold in Hep3B-Con clone
while a 291-fold increase was observed in Hep3B-SND1-17 clone.
Under basal condition no signiﬁcant difference was observed in
p549-luc activity between Hep3B-Con and Hep3B-SND1-17 clones.
Upon TGFb treatment p549-luc activity increased by 9-fold in
Hep3B-Con clone while a 17-fold increase was observed in
Hep3B-SND1-17 clone. The augmented activity of p800-luc and
the marked attenuation of the activity of p549-luc by SND1 and
TGFb indicate that SND1 and TGFb regulate PAI-1 expression by
modulating its transcription.
3.3. SND1 induces TGFb expression through AT1R signaling
We next sought for the molecular mechanism by which SND1
induces TGFb. Angiotensin II type 1 receptor (AT1R) induces TGFb
expression and previous studies have documented that SND1
increases AT1R level by augmenting AT1R mRNA stability [28].
We observed that AT1R protein level was signiﬁcantly increased
in Hep3B-SND1-17 clone compared to Hep3B-Con clone and was
signiﬁcantly downregulated in QGY-SND1si-12 and Huh7-
SND1si-7 clones when compared to QGY-Consi and Huh7-Consi
clones, respectively (Fig. 3A). Extracellular signal-regulated kinase
(ERK) and SMAD2 are downstream signal transduction molecule
from AT1R. Indeed, we observed increased activation of ERK and
Fig. 2. PAI-1 and TGFb promote migration and invasion of human HCC cells. (A and B) Hep3B-SND1-17 and QGY-7703 cells were transfected with either control scrambled
siRNA or PAI-1 siRNA and then subjected to migration (A) and Matrigel invasion (B) assay. (C and D) Hep3B cells were treated with recombinant PAI-1 or TGFb and migration
(C) and invasion (D) assays were performed. Migration ability of untreated Hep3B cells was considered as 100%. (E and F) QGY-SND1si-12 cells were treated with recombinant
PAI-1 (20 nmol/ml) or TGFb (1 nmol/ml) and migration (E) and invasion (F) assays were performed. Migration ability of untreated QGY-SND1si-12 cells was considered as
100%. For A–F, data represent mean ± SEM of 3 independent experiments. ⁄p < 0.01. (G) Analysis of the expression of the indicated markers of EMT in the indicated cells by
Western blot. b-actin was used as loading control. The numbers indicate densitometric quantiﬁcation when the level of each protein was divided by the level of b-actin and
the normalized levels in Hep3B-Con, QGY-Consi and Huh7 were considered as 1. (H) Analysis of human PAI-1 promoter luciferase activity using p800-luc and p549-luc in the
indicated cells. R.L.A.: relative luciferase activity. A.U.: arbitrary units of fold change when the luciferase activity of p800-luc in Hep3B-Con cells was considered as 1. Data
represent mean ± SEM of 3 independent experiments. ⁄p < 0.01 vs no treatment, #p < 0.01 vs p800-luc.
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and decreased activation in QGY-SND1si-12 and Huh7-SND1si-7
clones when compared to QGY-Consi and Huh7-Consi clones,
respectively, indicating that overexpression of AT1R might lead
to functional AT1R signaling (Fig. 3A). To conﬁrm that SND1
increases AT1R protein level by elevating AT1R mRNA stability
we treated Hep3B-Con, Hep3B-SND1-17 and Hep3B-SND1-9
clones with Actinomycin D to shut down transcription and deter-
mined AT1R mRNA level temporally. Under basal condition AT1R
mRNA level was signiﬁcantly higher in Hep3B-SND1-17 and
Hep3B-SND1-9 clones compared to Hep3B-Con clone (Fig. 3B).
Upon Actinomycin D treatment, at 4 h, AT1R mRNA level decreased
by 50% in Hep3B-Con clone while the level decreased by only 15%
in SND1-overexpressing clones (Fig. 3C) indicating that increased
stability of AT1R mRNA, conferred by SND1, might contribute to
increased AT1R protein level.
We analyzed SND1 and AT1R expression by immunohistochem-
istry in a tissue microarray containing 50 human HCC samples and
9 matched normal liver samples. A representative result from one
patient is shown in Fig. 3D. SND1 expression was virtually unde-
tectable in normal human liver while its expression was markedlyhigher in the HCC samples. Constitutive low level expression of
AT1R was detected in normal liver. However, its expression was
signiﬁcantly higher in the HCC samples. A statistically signiﬁcant
correlation (p < 0.0001) was observed between SND1 and AT1R
levels in these patients using a Pearson’s v2 goodness of ﬁt test
with 6 degrees of freedom further establishing the regulation of
AT1R by SND1 in the clinical situation (Fig. 3E).
To investigate the role of AT1R in mediating SND1-induced
migration and invasion we blocked AT1R using a speciﬁc chemical
inhibitor Losartan potassium (LP). Treatment of Hep3B-SND1-17,
QGY-7703 and Huh7 cells with LP (10 lM) signiﬁcantly inhibited
both migration and invasion (Fig. 4A and B). As a corollary, treat-
ment of Hep3B-SND1-17 and QGY-7703 cells with either AT1R siR-
NA or LP signiﬁcantly inhibited PAI-1 expression while a
combination of AT1R siRNA and LP resulted in further inhibition
in PAI-1 level indicating the involvement of AT1R in regulating
SND1-induced PAI-1 expression (Fig. 4C). It should be noted that
treatment of SND1-overexpressing and SND1-knockdown clones
with LP for 5 days did not signiﬁcantly affect cell viability as mea-
sured by standard MTT assay (Fig. 4D). However, in a 2-week long
clonogenic assay, LP treatment inhibited colony formation mod-
Fig. 3. AT1R is induced by SND1. (A) Analysis of the expression of the indicated proteins in the indicated cells byWestern blot. EF1a and GAPDHwere used as loading control.
The numbers indicate densitometric quantiﬁcation when the level of each protein was divided by the level of GAPDH and the normalized levels in Hep3B-Con, QGY-Consi and
Huh7 were considered as 1. (B) Basal AT1R mRNA level in the indicated cells determined by Taqman RT-PCR. A.U.: arbitrary units of fold change when AT1R mRNA level in
Hep3B-Con cells was considered as 1. (C) Hep3B-Con, Hep3B-SND1-17 and Hep3B-SND1-9 clones were treated with actinomycin D (5 lg/ml) for the indicated time point and
AT1R mRNA level was determined by Taqman RT-PCR. A.U.: arbitrary units of fold change when AT1R mRNA level in Hep3B-Con cells at 0 time point was considered as 1.
Data represent mean ± SEM of 3 independent experiments. ⁄p < 0.01. (D) Immunohistochemical analysis of SND1 and AT1R in normal liver and HCC samples, magniﬁcation
400. (E) Graph representing coexpression of SND1 and AT1R in normal liver and HCC of all stages. p < 0.0001 by Pearson’s v2 goodness of ﬁt test with 6 degrees of freedom.
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that AT1R-mediated signaling mainly regulates SND1-induced cell
motility rather than viability and proliferation.
To further conﬁrm the importance of AT1R in SND1 function we
established stable clones in the background of Hep3B-SND1-17
clone expressing AT1R siRNA. Compared to the control clones,
Consi-1 and Consi-2 stably expressing control, scrambled siRNA,
two independent AT1R siRNA expressing clones, AT1Rsi-3 and
AT1Rsi-12, showed signiﬁcantly decreased level of AT1R with cor-
responding decreased activation of ERK and SMAD2 (Fig. 5A).
AT1Rsi-3 and AT1Rsi-12 clones of Hep3B-SND1-17 clone showed
signiﬁcantly decreased migration (Fig. 5B), invasion (Fig. 5C), and
PAI-1 (Fig. 5D) and TGFb (Fig. 5E) expression, when compared to
Consi-1 and Consi-2 clones.3.4. ERK mediates SND1-induced migration and invasion
Since ERK activation is markedly augmented by SND1 we next
checked the effect of ERK inhibition by PD184352 on SND1-
induced migration and invasion. Treatment of Hep3B-SND1-17,
QGY-7703 and Huh7 cells with PD184532 (20 lM) signiﬁcantly
inhibited both migration and invasion (Fig. 6A and B). Treatment
of Hep3B-SND1-17 and QGY-7703 cells with PD184532 signiﬁ-
cantly inhibited PAI-1 expression (Fig. 6C). These ﬁndings were
extended further by treating Hep3B-SND1-17 clone with
PD184532 for 2 h in serum-free medium and then using the condi-
tioned media for a protein array that detects 55 proteins regulating
invasion, angiogenesis and metastasis. PD184532 treatment
resulted in signiﬁcant downregulation of 11 proteins, including
Fig. 4. Chemical inhibition of AT1R abrogates migration and invasion by human HCC cells. (A and B) The indicated cells were treated with losartan potassium (LP; 10 lM) and
migration (A) and Matrigel invasion (B) were analyzed. (C) The indicated cells were transfected with either control, scrambled siRNA or AT1R siRNA and treated or not with LP
and PAI-1 level in the conditioned media was determined by ELISA. (D) The indicated cells were treated with LP for 5 days and cell viability was determined by standard MTT
assay. Cell viability of untreated Hep3B-Con clone was considered as 100%. (E) The indicated cells were treated with LP for 2 weeks and clonogenic assay was performed. For
A–E, data represent mean ± SEM of 3 independent experiments. ⁄p < 0.01.
Fig. 5. Genetic inhibition of AT1R abrogates migration and invasion by human HCC cells. Consi-1 and Consi-2 are stable clones of Hep3B-SND1-17 clone expressing control,
scrambled shRNA. AT1Rsi-3 and AT1Rsi-12 are stable clones of Hep3B-SND1-17 clone expressing AT1R shRNA. (A) The expression of the indicated proteins were determined
in the indicated cells by Western blot. b-actin was used as loading control. The numbers indicate densitometric quantiﬁcation when the level of each protein was divided by
the level of b-actin and the normalized level in Consi-1 was considered as 1. (B and C) Migration (B) and Matrigel invasion (C) assays were performed in the indicated clones.
(D and E) PAI-1 (D) and TGFb (E) levels were determined in the conditioned media of the indicated cells. For B–E, data represent mean ± SEM of 3 independent experiments.
⁄p < 0.01.
P.K. Santhekadur et al. / FEBS Open Bio 4 (2014) 353–361 359PAI-1 (Fig. 6D and S2). The combined downregulation of these
regulatory factors by PD184532 indicates the importance of
ERK in mediating SND1-induced invasion, angiogenesis and
metastasis.
4. Discussion
Although the role of AngII/AT1R is well-established in hepatic
ﬁbrosis via modulating HSC and in tumor angiogenesis by regu-
lating functions of endothelial cells, the contribution of thissignaling pathway to regulate other aspects of hepatocarcinogen-
esis has not been clearly demonstrated. In the present studies we
delineate a novel molecular mechanism linking SND1 and
AT1R with subsequent activation of TGFb signaling contributing
to EMT and migration and invasion by human HCC cells.
These ﬁndings extend our previous observation that SND1 aug-
ments tumor angiogenesis through NF-jB, miR-221, Angiogenein,
and CXCL16 [12]. SND1 thus contributes to all the hallmarks of
cancer by multiple mechanisms inducing a highly aggressive
cancer.
Fig. 6. Inhibition of ERK abrogates migration and invasion by human HCC cells. (A and B) The indicated cells were treated with PD183452 (20 lM) and were subjected to
migration (A) and Matrigel invasion (B) assays. (C) The indicated cells were treated with PD183452 and PAI-1 level in the conditioned media was determined by ELISA. (D)
Hep3B-SND1-17 cells were treated with PD183452 and the conditioned media was used for a protein array. For A–C, data represent mean ± SEM of 3 independent
experiments. ⁄p < 0.01.
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untranslated region (30-UTR) of AT1R mRNA via the nuclease
domains resulting in increased AT1R expression by decreasing
the rate of mRNA decay and enhancing translation [28]. This func-
tion of SND1 is independent of its function in RISC where it facili-
tates mRNA degradation [28,29]. We also document that the level
of AT1R protein is increased in SND1-overexpressing cells and
decreased in SND1-knockdown cells and our mRNA stability stud-
ies using actinomycin D clearly demonstrates increased half-life of
AT1R mRNA in SND1-overexpressing clones compared to control
clone. As yet AT1R overexpression in human HCC patients has
not been documented and we observed a signiﬁcant statistical cor-
relation between SND1 and AT1R levels in HCC samples versus
normal liver. Thus a post-transcriptional regulation of AT1R by
SND1 might play an important role in promoting aggressive
progression of HCC. This overexpression of AT1R might lead to its
constitutive activation since we observed activation of down-
stream signaling pathways without addition of natural AT1R ligand
angiotensin II. The factors that determine whether SND1 will
function as a component of RISC or promote mRNA stability remain
to be identiﬁed. Search for a SND1 recognition motif, present in
AT1R 30-UTR, in other mRNAs might identify additional SND1 tar-
gets and provide an explanation of preferential selection of SND1
in executing its function.
There might be multiple ways by which SND1 regulates TGFb
signaling cascade. TGFb signaling through TGFbR1 promotes
tumorigenesis while that through TGFbR2 functions as a tumor
suppressor [30]. We previously documented that as part of RISC
SND1 promotes degradation of TGFbR2 mRNA, a target of the
oncogenic miRNA-93, thus facilitating the oncogenic TGFb/TGFbR1
signaling [11]. A promoter microarray study based on chromatinimmunoprecipitation-guided ligation and selection (ChIP-GLAS)
identiﬁed binding of SND1 to the promoter region of several mem-
bers of the TGFb signaling pathway and it was documented that
overexpression of SND1 augmented expression of the correspond-
ing mRNAs [31]. However, whether TGFb itself is regulated by
SND1 was not addressed in that study. We document that SND1-
induced AT1R activation increases TGFb expression. Our micro-
array studies identiﬁed downregulation of TGFb downstream
genes in SND1-knockdown clones compared to control clones.
Additionally, our previous protein array studies identiﬁed regula-
tion of TGFb downstream proteins, such as PAI-1 and IGFBP3, by
SND1 [12]. We employed PAI-1 as a read-out of SND1–AT1R–TGFb
function because of its known role in regulating migration, inva-
sion and angiogenesis [27]. However, it might be the concerted
efforts of multiple TGFb downstream genes that bring forth the
profound phenotypic effect observed upon SND1 manipulation.
AT1R activation by SND1 leads to activation of ERK and SMAD2
signaling that might exert both TGFb-mediated and TGFb-indepen-
dent effects. Indeed protein array studies reveal that inhibition of
ERK abrogated expression of not only PAI-1 and IGFBP3 but also
TIMP-1 and IL-8, known targets of AngII/AT1R signaling, markedly
[13]. Inhibition of ERK resulted in signiﬁcant inhibition of migra-
tion and invasion by human HCC cells. ERK activation plays a piv-
otal role in hepatocarcinogenesis and activated ERK is a potential
tissue biomarker for HCC [32]. Our observation linking SND1 over-
expression with ERK activation confers added importance to the
regulatory role of SND1 in HCC development and progression.
Our current and previous studies reveal that SND1 activates
multiple pro-oncogenic signaling, such as NF-jB, AngII/AT1R, ERK
and TGFb. Removal of Smad2, AP-1 and NF-jB binding sites from
PAI-1 promoter profoundly abrogated PAI-1 promoter activity in
P.K. Santhekadur et al. / FEBS Open Bio 4 (2014) 353–361 361SND1-overexpressing clones suggesting that PAI-1 expression
itself might be regulated by multiple signaling pathways activated
by SND1. SND1 thus might be a nodal point in hepatocarcinogene-
sis and SND1 inhibitors might serve as novel and effective
therapeutic approach for HCC.
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